Angiotensin-Rezeptor-Antagonisten: Eine neue Klasse von Antihypertonika

Deutsche Medizinische Wochenschrift

Volumn 121, Issue 17, 1996, Pages 568-571

  Mann, J ^a,b  

^a Klinikum Schwabing   (Germany)

^b Stadtisches Krankhs M Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; IMIDAZOLE DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN;

ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; HYPERTENSION; REVIEW; DRUG EFFECT; DRUG EFFICACY; SHORT SURVEY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0029970973     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043041     Document Type: Article

References (22)

1. Acker, C. A., A. Greenberg: Angioedema induced by the angiotensin II blocker losartan. New Engl. J. Med. 333 (1995), 1572.
2. Burnier, M., M. Hagmann, J. Nussberger, J. Biollaz, C. Armagnac, R. Brouard, B. Waeber, H. R. Brunner: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25 (1995), 602-609.
3. Chan, J. C. N., J. Chritchley, J. T. Lappe, S. J. Raskin, D. Snavely, A. I. Goldberg, C. S. Sweet: Randomised, double-blind, parallel study of the antihypertensive efficacy and safety of losartan compared with felodipine ER in elderly patients with mild to moderate hypertension. J. hum. Hypertens. 9 (1995), 765-771.
4. Christen, Y., B. Waeber, J. Nussberger, M. Prchet, R. M. Borland, R. J. Lee, K. Maggon, L. Shum, P. B. M. W. M. Timmermans, H. R. Brunner: Oral administration of DuP 753, a specific angiotensin II receptor antagonist. Circulation 83 (1991), 1333-1342.
5. Crozier, I., H. Ikram, N. Awan, J. Cleland, N. Stephen, K. Dickstein, M. Frey, J. Young, G. Klinger, L. Makris, E. Rucinska: Losartan in heart failure. Circulation 91 (1995), 691-697.
6. Dahlöf, B., S. E. Keller, L. Makris, A. I. Goldberg, C. S. Sweet, N. Y. Lim: Efficacy and tolerability of losartan and atenolol in patients with mild to moderate essential hypertension. Amer. J. Hypertens. 8 (1995), 578-583.
7. Doig, J. K., R. J. MacFadyen, C. S. Sweet, J. L. Reid: Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J. Cardiovasc. Pharmacol. 25 (1995), 511-517.
8. Gansevoort, R. T., D. deZeeuw, P. deJong: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney int. 45 (1994), 861-867,
9. Goldberg, A. I., M. C. Dunlay, C. S. Sweet: Safety and tolerability of losartan, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Amer. J. Cardiol. 75 (1995), 793-795.
10. Goldberg, M. R., T. E. Bradstreet, E. J. McWilliams, W. K. Tanaka, S. Lipert, T. D. Bjornsson, S. A. Waldman, B. Osborne, L. Pivadori, G. Lewis, R. Blum, T. Herman, P. A. Abraham, C. N. Halstenson, M. W. Lo, H. Lu, R. Spector: Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25 (1995), 37-46.
11. Gradman, A. H., K. E. Arcuri, A. I. Goldberg, L. S. Ikeda, E. B. Nelson, D. B. Snavely, C. S. Sweet: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 25 (1995), 1345-1350.
12. Johnston, C. I.: Angiotensin receptor antagonists: focus on losartan. Lancet 346 (1995), 1403-1407.
13. Lacourcière, Y., H. Brunner, R. Irwin, B. E. Karlberg, L. E. Ramsay, D. B. Snavely, T. W. Dobbins, E. P. Faison, E. B. Nelson, the Losartan Cough Study Group: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J. Hypertens. 12 (1994), 1387-1393.
14. MacFadyen, R. J., J. L. Reid: Angiotensin receptor antagonists as a treatment for hypertension. J. Hypertens. 12 (1994), 1333-1338.
15. Mann, J. F. E., R. Dietz, E. Ritz, D. Ganten: Different antagonist potency of saralasin in acute and chronic angiotensin-dependent hypertension. Europ. J. Pharmacol. 92 (1993), 207-213.
16. Meiracker van den, A., P. J. J. Admiraal, J. A. Janssen, J.-M. Kroodsma, W. A. M. de Ronde, F. Boomsma, J. Sissmann, P. J. Blankenstijn, P. G. M. Mulder, A. J. Man in 't Veld, M. A. D. H. Schalekamp: Hemodynamic and biochemical effects of the AT 1 receptor antagonist irbesartan in hypertension. Hypertension 25 (1995), 22-29.
17. Moan, A., T. Risanger, I. Eide, S. E. Kjeldsen: The effect of angiotensin H receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Pressure 3 (1994), 185-188.
18. Munafo, A., Y. Christen, J. Nussberger, L. Y. Shum, R. M. Borland, R. J. Lee, B. Waeber, J. Biollaz, H. R. Brunner: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin. Pharmacol. Ther. 51 (1992), 513-521.
19. Nakashima, M., T. Uematsu, K. Kosuge, M. Kanamura: Pilot study of the uricosuric effect of DUP 753, a new angiotensin II receptor antagonist, in healthy subjects. Europ. J. Pharmacol. 42 (1992), 333-335.
20. Tanaka, R., V. Kon, T. Yoshioka, I. Ichikawa, A. Fogo: Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney int. 45 (1994), 537-543.
21. Timmermans, P. B. M. W. M., P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. M. Saye, R. D. Smith: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 2 (1993), 205-251.
22. Weber, M. A., R. L Bryyny, H. Pratt, E. P. Faison, D. B. Snavely, A. I. Goldberg, E. B. Nelson: Blood pressure effects of the angiotensin II receptor blocker losartan. Arch. intern. Med. 155 (1995), 405-411.